Fecal Microbiota Transplantation (FMT) Market Report 2026

The fecal microbiota transplantation (fmt) market size has grown strongly in recent years. It will grow from $0.91 billion in 2025 to $0.98 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to recognition of gut microbiome role in disease, success of fmt in recurrent cdi cases, expansion of hospital-based fmt programs, early regulatory guidance on microbiome therapies, availability of stool banks.

The fecal microbiota transplantation (fmt) market size is expected to see strong growth in the next few years. It will grow to $1.27 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing research into microbiome-based therapeutics, rising demand for standardized fmt formulations, expansion of indications beyond gastrointestinal diseases, growing investment in microbiome biotechnology, advancement in oral delivery technologies. Major trends in the forecast period include increasing standardization of donor screening protocols, rising adoption of cryopreserved fmt products, growing clinical acceptance beyond cdi treatment, expansion of capsule-based administration methods, enhanced focus on microbiome analytics.

The rising prevalence of gastrointestinal disorders is expected to drive the growth of the fecal microbiota transplantation (FMT) market in the coming years. Gastrointestinal (GI) disorders encompass a wide range of conditions affecting the gastrointestinal tract, including the esophagus, stomach, small intestine, large intestine (colon), rectum, and anus. The increase in these disorders is linked to higher stress levels, sedentary lifestyles, and greater consumption of processed foods. Fecal microbiota transplantation is used to restore healthy gut bacteria, particularly for treating recurrent Clostridioides difficile infections. For example, in 2023, Crohn's and Colitis Canada, a Canada-based non-profit organization, reported that the number of people with IBD is projected to grow from 322,600 in 2023 (0.8% of the population) to 470,000 in 2035 (1.1% of the population). In 2023, 11,000 new diagnoses are expected (one every 48 minutes), rising to 14,000 by 2035 (one every 38 minutes). Consequently, the growing prevalence of gastrointestinal disorders is driving the expansion of the FMT market.

Major companies in the FMT market are focusing on developing standardized microbiota-based therapies, such as fecal microbiota spores (live-brpk), to enhance safety, patient compliance, treatment consistency, and scalability. Fecal microbiota spores (live-brpk) are highly processed donor-derived microbial spores produced under strict screening and purification protocols to restore healthy gut microbiota with controlled dosing and reduced infection risk. For instance, in April 2023, Seres Therapeutics, a US-based microbiome therapeutics company, received FDA approval for VOWST, a fecal microbiota spores (live-brpk) therapy designed to prevent recurrence of Clostridioides difficile infection in adults. The therapy features oral capsule delivery, a defined microbial spore composition, and rigorous pathogen-screening protocols, improving treatment convenience, safety, and commercial scalability in the FMT sector.

In September 2024, Metagen Therapeutics, Inc., a Japan-based biotechnology startup, partnered with JSR Corporation to establish an investigational-drug manufacturing facility for FMT drugs. Through this partnership, Metagen Therapeutics and JSR aim to produce and scale oral FMT drug candidates, initiate preclinical and clinical trials, enhance manufacturing and quality control of microbiome-based therapies, and accelerate the delivery of FMT-derived treatments to patients. JSR Corporation, a Japan-based materials and life-sciences company, is providing manufacturing infrastructure and development expertise for microbiome medicines.

Major companies operating in the fecal microbiota transplantation (fmt) market are Ferring Pharmaceuticals, Johns Hopkins Medicine, Seres Therapeutics, Taconic Biosciences, Enterome, Rebiotix Inc, Finch Therapeutics Group Inc, Locus Biosciences, Yeda Research and Development Co. Ltd, Microbiotica Limited, CosmosID Inc, AOBiome, Synthetic Biologics Inc., Osel Inc., OpenBiome, Asia Microbiota Bank, Taymount Clinic, MicroBiome Therapeutics LLC, MaaT Pharma SA, Kallyope.

North America was the largest region in the fecal microbiota transplantation (FMT) market in 2025. The regions covered in the fecal microbiota transplantation (fmt) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fecal microbiota transplantation (fmt) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the fecal microbiota transplantation market by increasing costs of imported laboratory equipment, cryopreservation systems, diagnostic reagents, and pharmaceutical-grade capsules used in fmt preparation and administration. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported biotech inputs, while Asia-Pacific faces cost pressures on research and processing infrastructure. These tariffs are increasing procedural costs and limiting rapid scalability. However, they are also supporting localized production of fmt materials, domestic stool banking initiatives, and regional microbiome research capabilities.

The fecal microbiota transplantation (fmt) market research report is one of a series of new reports that provides fecal microbiota transplantation (fmt) market statistics, including fecal microbiota transplantation (fmt) industry global market size, regional shares, competitors with a fecal microbiota transplantation (fmt) market share, detailed fecal microbiota transplantation (fmt) market segments, market trends and opportunities, and any further data you may need to thrive in the fecal microbiota transplantation (fmt) industry. This fecal microbiota transplantation (fmt) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fecal microbiota transplantation (FMT) is a medical procedure in which fecal material from a healthy donor is transplanted into a recipient’s gastrointestinal tract to restore the balance of beneficial gut microorganisms. This procedure is primarily used to treat conditions in which the gut microbiota is disrupted, such as recurrent Clostridioides difficile infection (CDI) that does not respond to conventional treatments.

The main types of FMT include fermentation-based, fresh, and cryopreserved methods. Fermentation in FMT refers to the process by which gut bacteria break down complex carbohydrates and fibers in the gastrointestinal tract, producing short-chain fatty acids and other metabolites that support gut health. Donor material can be stool-derived, fecal-derived, or whole-microbiome derived, and is used to manage various conditions, including Clostridioides difficile infection, inflammatory bowel disease, metabolic syndrome, and others. FMT is administered via oral, rectal, nasogastric, and colon capsule routes. The primary end users include hospitals, specialty clinics, and other healthcare facilities.

The fecal microbiota transplantation (FMT) market consists of revenues earned by entities by providing services such as donor screening and testing, microbiome assessment, stool collection, processing and preparation, endoscopic delivery, clinical monitoring, and symptom management. The market value includes the value of related goods sold by the service provider or included within the service offering. The fecal microbiota transplantation (FMT) market also includes sales of oral capsules, colonoscopy-based FMT, nasogastric or nasoduodenal tube and lyophilized (freeze-dried) stool. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.